CRP and COVID-19: Although in one case, the application of N-acetylcysteine (NAC), a ferroptosis inhibitor that promotes glutathione supplementation, restored glutathione levels in the SARS-CoV-2-infected cells, and markedly reduced C-reactive protein (CRP) levels in a severe COVID-19 patient, and another randomized clinical trial indicated that a high dose of NAC brought little benefit to hindering the evolution of severe COVID-19 [65,66,67].